

Date: 20/08/2026
Our Ref: 11740
Enquiries to loth.freedomofinformation@nhs.scot

Dear

FREEDOM OF INFORMATION – ONCOLOGY TREATMENT

I write in response to your request for information in relation to oncology treatment in NHS Lothian.

Question:

1. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

Myelofibrosis (ICD10 code D47.4)

Polycythaemia Vera (ICD10 code D45)

Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005)

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Ruxolitinib (Jakavi) treatment, NHS Lothian	
Diagnosis	Number of patients
Myelofibrosis	≤5
Polycythaemia Vera	0
Graft vs Host Disease	0

Question:

2. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

Momelotinib

Fedratinib

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patient treatment, NHS Lothian	
Name of medicine	Number of patients
Momelotinib	≤5
Fedratinib	0

Question:

3. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

Hydroxycarbamide
Interferon therapy

Answer:

The information you have requested is detailed in the table below.

Treatment for Polycythaemia Vera, NHS Lothian	
Name of medicine	Number of patients
Hydroxycarbamide	37
Interferon therapy	13

Question:

4. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Ruxolitinib (Jakavi); Fedratinib (Inrebic); Momelotinib (Omjjara)

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the

information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Myelofibrosis treatment, NHS Lothian		
Name of medicine	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	≤5	7
Fedratinib (Inrebic)	0	≤5
Momelotinib (Omjjara)	≤5	7

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI>

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive